Patent Application Attorney Docket No.PC10343C

(Signature of person mailing) Madeline Deveran (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE N RE APPLICATION OF: Graham Maw, et al.

10/686,349 APPLICATION NO.:

Examiner: To Be Assigned

FILING DATE:

October 15, 2003

Group Art Unit: 1617

Compounds for the Treatment of Female Sexual: TITLE:

Dysfunction

Mail Stop Amendment

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708,392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-4288

Martha G. Munchhof

Attorney for Applicant(s)

Reg. No. 47,811

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC10343C SERIAL NO.10,686,349 (Use several sheets if necessary) APPLICANT Graham Nigel Maw, et al. **GROUP** FILING DATE October 15, 2003 1617 **U.S. PATENT DOCUMENTS** EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE IF APPROPRIATE INITIAL 7S.K./ US 9 6-7-88 Kruse, Lawrence 514 392 /S.K./ US 5 3 4 6 9 0 1 9-13-94 Bell, et al 514 258 Equivalent to RU2114114 /S.K./ US 7 Bell, et al 258 6 2 3 5 4 5-22-01 514 2 /S.K./ 7 8 263.1 US 6 3 4 6 5-11-04 Maw, et al 514 **FOREIGN PATENT DOCUMENTS** COUNTRY TRANSLATION DOCUMENT NUMBER DATE CLASS SUBCLASS YES NO /S.K. wo 9 8 5 2 8 9 0 11-26-98 International C07C 21/00 /S.K WO 9 0 2-26-98 International A61K 31/34 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) S.K./ Beavo, et al, TIPS Reviews, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", Vol. 11, pp. 150-155, (1990) /S.K. Brandenburg, et al., The Journal of Neuroscience, "Identification Of Endogenous Sympathetic Neuron Pituitary Adenylate Cyclase-Activating Polypeptide (PACCAP): Depolarization Regulates Production And Secretion Through Induction Of Multiple Propeptide Transcripts", Vol. 17(11) pp. 4045-4055 (1997) /S.K./ May, et al., The Journal of Neuroscience, "Differential Regulation of sympathetic Neuron Neuropeptide Y and Catecholamine Content and Secretion", Vol. 15(6), pp. 4580-4591, (1995) /S.K./ May, et al., <u>Journal of Neurochemistry</u>, "Pituitary Adenylate Cyclase-Activitating Polypeptide (PACAP) Regulation Of Sympathetic Neuron Neuropeptide Y And Catecholamine Expression", Vol. 65, pp. 978-987 (1995) /S.K. Zusman, et al., American Journal of Cardiology, "Overall Cardiovascular Profile Of Sildenafil Citrate", Vol. 83, pp. 35C-44C, (1999) /S.K. US Application #09.708,392, filed November 8, 2000, Maw et al, Patent US6734186 filed May 11, 2004 /S.K. US Application #09/895,367, filed June 29, 2001, Naylor, et al /S.K. U.S. 2003/0027824, filed February 6, 2003; Ellis, et al., 514/234.5 equivalent to RU2130776 /S.K. U.S. 2003/0067945, filed April 8, 2004; Niewohner, et al., ., 514/234 equivalent to WO99/24433 DATE CONSIDERED 09/02/2008 /Shobha Kantamneni/

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE